Metabolism of fibric acid derivatives [1]

Clinical Pharmacokinetics

Volumn 34, Issue 5, 1998, Pages 419-420

  Spence, J D ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIBEFRADIL; SIMVASTATIN; WARFARIN;

DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; HUMAN; LETTER; LIVER METABOLISM; PRIORITY JOURNAL;

EID: 0031945752     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834050-00006     Document Type: Letter

References (12)

1. 1. D.B. Miller J.D. Spence 1998 Clinical pharmacokinetics of fibric acid derivatives (fibrates) Clin Pharmacokinet 34 155 62 9515185 10.2165/00003088-199834020-00003 1:CAS:528:DyaK1cXhsFaisrw%3D Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998; 34: 155–62.
2. 2. Antilipemic agents. In 1997 G.K. McEvoy AHFS 97 Drug Information Board of Directors, American Society of Health System Pharmacists Bethesda (MD) 1346 Antilipemic agents. In: McEvoy GK, editors. AHFS 97 Drug Information. Bethesda (MD): Board of Directors, American Society of Health System Pharmacists, 1997: 1346.
3. 3. A. Lozada C.A. Dujovne 1994 Drug interactions with fibric acids Pharmacol Ther 63 2 163 76 7809177 10.1016/0163-7258(94)90043-4 1:CAS:528:DyaK2cXmt1SrtLg%3D Lozada A, Dujovne CA. Drug interactions with fibric acids. Pharmacol Ther. 1994; 63(2): 163–76.
4. 4. L.S. Kaminsky Z.Y. Zhang 1997 Human P450 metabolism of warfarin Pharmacol Ther 73 67 74 9014207 10.1016/S0163-7258(96)00140-4 1:CAS:528:DyaK28Xns1Cjsrw%3D Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997; 73: 67–74.
5. 5. J. Feely P. O’Connor 1991 Effects of HMG CoA reductase inhibitors on warfarin binding Drug Invest 5 315 6 Feely J, O’Connor P. Effects of HMG CoA reductase inhibitors on warfarin binding. Drug Invest. 1991; 5: 315–6.
6. 6. S. Urien E. Albengres R. Zini 1980 Serum binding and interactions of chlorphenoxyisobutyric acid, itanoxone and fenofibric acid according to their different HSA binding sites R. Famagalli D. Kritchevsky R. Paoletti Drugs affecting lipid metabolism Elsevier/North Holland Biomedical Press Amsterdam 201 9 Urien S, Albengres E, Zini R, et al. Serum binding and interactions of chlorphenoxyisobutyric acid, itanoxone and fenofibric acid according to their different HSA binding sites. In: Famagalli R, Kritchevsky D, Paoletti R, editors. Drugs affecting lipid metabolism. Amsterdam: Elsevier/North Holland Biomedical Press, 1980: 201–9.
7. 7. C. Transon L. Thierry N. Vogt 1995 In vivo inhibition profile of cytochrome P450 tb CYP2C9) by (±) fluvastatin Clin Pharmacol Ther 58 412 7 7586933 10.1016/0009-9236(95)90054-3 1:CAS:528:DyaK28XhslKrsw%3D%3D Transon C, Thierry L, Vogt N, et al. In vivo inhibition profile of cytochrome P450 tb CYP2C9) by (±) fluvastatin. Clin Pharmacol Ther. 1995; 58: 412–7.
8. 8. K.S. Lown R. Mayo A.B. Leichtman 1997 Role of intestinal p-glycoprotein (mdr 1) in interpatient variation in the oral bioavailability of cyclosporine Clin Pharmacol Ther 62 248 60 9333100 10.1016/S0009-9236(97)90027-8 1:CAS:528:DyaK2sXmslOrt7g%3D Lown KS, Mayo R, Leichtman AB, et al. Role of intestinal p-glycoprotein (mdr 1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997; 62: 248–60.
9. 9. R.S. Lees A.M. Lees 1995 Rhabdomyolysis from the co-administration of lovastatin and the anti-fungal agent itraconazole N Engl J Med 333 664 7637734 10.1056/NEJM199509073331015 1:STN:280:DyaK2MzmsVyksw%3D%3D Lees RS, Lees AM. Rhabdomyolysis from the co-administration of lovastatin and the anti-fungal agent itraconazole. N Engl J Med. 1995; 333: 664.
10. 10. P.J. Neuvonen K.-M. Jalava 1996 Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid Clin Pharmacol Ther 60 54 61 8689812 10.1016/S0009-9236(96)90167-8 1:CAS:528:DyaK28XltFSqu7o%3D Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996; 60: 54–61.
11. 11. Mibebradil interaction with simvastatin. Http://www.posicor.com/posicor/content/prescribe.html#CONTRAINDICATIONS. [Accessed 1998 March 30].
12. 12. R. Goldberg D. Roth 1996 Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine Transplantation 62 11 1559 64 8970607 10.1097/00007890-199612150-00005 1:CAS:528:DyaK2sXjtVWitg%3D%3D Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation. 1996; 62(11): 1559–64.